Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer in disguise: a parasite within.

The EMBO journal·2026

Same author

The role of innate immune cells in modulating vascular dynamics in skin malignancies.

Biochimica et biophysica acta. Reviews on cancer·2025

Same author

Reinventing type 2 immunity in cancer.

Nature·2025

Same author

Distinguishable topology of the task-evoked functional genome networks in HIV-1 reservoirs.

iScience·2024

Same author

Contribution of initial lymphatics to oral wound healing after tooth extraction.

European journal of oral sciences·2024

Same author

Innate lymphoid cells and tumor-derived lactic acid: novel contenders in an enduring game.

Frontiers in immunology·2023

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

IL-33 scripts cancer immunity.

¹Innate Immunity Research Group, Population Diagnostics Center, Łukasiewicz Research Network - PORT Polish Center for Technology Development, Wrocław, Poland; Department of Oncology and Haematology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland.

Trends in Immunology

|July 2, 2026

Summary

This summary is machine-generated.

Interleukin-33 (IL-33) acts beyond initiating immunity in cancer. This research proposes IL-33 directs immune responses, influencing outcomes toward antitumor or suppressive states.

Keywords:

IL-33 alarmins immunity inflammation tumor microenvironment

Related Experiment Videos

Last Updated: Jul 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

Immunology
Cancer Biology
Molecular Biology

Background:

Interleukin-33 (IL-33) is traditionally recognized as an alarmin.
Its role in cancer extends beyond simple immune initiation.

Purpose of the Study:

To propose a novel framework for understanding IL-33's function in cancer.
To explore how IL-33 regulates the trajectory of host immune responses in the tumor microenvironment.

Main Methods:

Conceptual framework development.
Review and synthesis of existing literature on IL-33 and cancer immunology.

Main Results:

IL-33 is hypothesized to orchestrate immune responses through multiple regulatory layers.
These regulatory layers determine whether the host response leads to productive antitumor immunity or a suppressive, repair-like state.

Conclusions:

IL-33 plays a dynamic and regulatory role in cancer immunity, not just an initiating one.
Understanding IL-33's multifaceted functions is crucial for developing effective cancer immunotherapies.